Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial-Reference-Cited by-同舟云学术

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

Published:2020-06 Issue:6 Volume:21 Page:786-795
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Shu Catherine A,Gainor Justin F,Awad Mark M,Chiuzan Codruta,Grigg Claud M,Pabani Aliyah,Garofano Robert F,Stoopler Mark B,Cheng Simon K,White Abby,Lanuti Michael,D'Ovidio Frank,Bacchetta Matthew,Sonett Joshua R,Saqi Anjali,Rizvi Naiyer A

Funder

Genentech

Gilead Sciences

AstraZeneca

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019

2. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

3. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018